NewSquare Capital LLC Grows Position in Gilead Sciences, Inc. (GILD)
NewSquare Capital LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,446 shares of the biopharmaceutical company’s stock after purchasing an additional 694 shares during the period. NewSquare Capital LLC’s holdings in Gilead Sciences were worth $952,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in GILD. Waldron LP lifted its holdings in Gilead Sciences by 20.4% during the 1st quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock worth $711,000 after purchasing an additional 1,752 shares during the last quarter. WealthTrust Axiom LLC lifted its holdings in Gilead Sciences by 20.3% during the 1st quarter. WealthTrust Axiom LLC now owns 19,541 shares of the biopharmaceutical company’s stock worth $1,327,000 after purchasing an additional 3,303 shares during the last quarter. Pegasus Partners Ltd. lifted its holdings in Gilead Sciences by 36.2% during the 1st quarter. Pegasus Partners Ltd. now owns 18,724 shares of the biopharmaceutical company’s stock worth $1,272,000 after purchasing an additional 4,980 shares during the last quarter. Conning Inc. lifted its holdings in Gilead Sciences by 241.0% during the 1st quarter. Conning Inc. now owns 120,564 shares of the biopharmaceutical company’s stock worth $8,189,000 after purchasing an additional 85,212 shares during the last quarter. Finally, Dowling & Yahnke LLC lifted its holdings in Gilead Sciences by 1.0% during the 1st quarter. Dowling & Yahnke LLC now owns 48,601 shares of the biopharmaceutical company’s stock worth $3,301,000 after purchasing an additional 492 shares during the last quarter. 73.97% of the stock is owned by institutional investors and hedge funds.
In related news, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 40,000 shares of the firm’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the completion of the sale, the executive vice president now directly owns 137,488 shares in the company, valued at $10,174,112. The disclosure for this sale can be found here. Insiders sold 486,819 shares of company stock worth $39,298,919 over the last three months. 1.30% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/18/newsquare-capital-llc-grows-position-in-gilead-sciences-inc-gild.html.
Several analysts recently weighed in on GILD shares. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price target for the company in a report on Wednesday, September 6th. Morgan Stanley reissued an “equal weight” rating and set a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, ValuEngine cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 13th. Twelve equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $85.80.
Gilead Sciences, Inc. (GILD) opened at 80.24 on Wednesday. The stock has a 50 day moving average price of $82.48 and a 200-day moving average price of $72.25. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The firm has a market capitalization of $104.79 billion, a P/E ratio of 8.72 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. During the same period last year, the firm earned $3.08 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post $8.73 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a $0.52 dividend. The ex-dividend date was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.59%. Gilead Sciences’s payout ratio is presently 22.58%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.